| Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? |
21 |
| Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration |
18 |
| Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study |
17 |
| The Swedish motor neuron disease quality registry |
15 |
| Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial |
12 |
| Amyotrophic lateral sclerosis in Nordland county, Norway, 2000-2015: prevalence, incidence, and clinical features |
12 |
| A novel D90_K91insN mutation in exon 4 of the SOD1 gene caused familial amyotrophic lateral sclerosis in a Chinese pedigree |
12 |
| Neurofilaments in pre-symptomatic ALS and the impact of genotype |
12 |
| ALS longitudinal studies with frequent data collection at home: study design and baseline data |
11 |
| Experience with telemedicine in a multi-disciplinary ALS clinic |
11 |
| Spanish adaptation of the edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS) |
10 |
| The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public |
10 |
| Split-hand index in amyotrophic lateral sclerosis: an F-wave study |
9 |
| Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015 |
9 |
| ALS reversals: demographics, disease characteristics, treatments, and co-morbidities |
8 |
| Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch |
8 |
| Evaluation of remote pulmonary function testing in motor neuron disease |
8 |
| Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects |
8 |
| Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system |
8 |
| Screening for cognitive and behavioral change in amyotrophic lateral sclerosis/motor neuron disease: a systematic review of validated screening methods |
8 |
| Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta-analysis |
8 |
| An epidemiologic investigation of amyotrophic lateral sclerosis in Thrace, Turkey, 2006-2010* |
8 |
| Defining pre-symptomatic amyotrophic lateral sclerosis |
7 |
| Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis |
7 |
| Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial |
7 |
| Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002-2014: a retrospective population-based study |
7 |
| Amyotrophic lateral sclerosis and food intake |
7 |
| Patterns of symptom development in patients with motor neuron disease |
7 |
| Unveiling early cortical and subcortical neuronal degeneration in ALS mice by ultra-high field diffusion MRI |
7 |
| The TiM system: developing a novel telehealth service to improve access to specialist care in motor neurone disease using user-centered design |
7 |
| Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh Cognitive and Behavioral ALS screen (ECAS) |
7 |
| Riluzole does not improve lifespan or motor function in three ALS mouse models |
7 |
| VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics |
6 |
| Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium |
6 |
| Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations |
6 |
| A neuropsychological and behavioral study of PLS |
6 |
| Identification and functional analysis of novel mutations in the SOD1 gene in Chinese patients with amyotrophic lateral sclerosis |
6 |
| Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach |
6 |
| Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen |
6 |
| Early post-marketing experience with edaravone in an unselected group of patients with ALS |
6 |
| Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly |
5 |
| The burden of apathy for caregivers of patients with amyotrophic lateral sclerosis |
5 |
| Risk factors for social withdrawal in amyotrophic lateral sclerosis/motor neurone disease |
5 |
| Loss of functional connectivity is an early imaging marker in primary lateral sclerosis |
5 |
| Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates |
5 |
| A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis |
5 |
| Amyotrophic lateral sclerosis among patients with a Medicare Advantage prescription drug plan; prevalence, survival and patient characteristics |
5 |
| Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) |
5 |
| A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013 |
5 |
| Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance |
5 |
